Skip to main content

Month: August 2024

PainReform Provides Business Update for the Second Quarter of 2024

Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expected to significantly enhance future commercialization efforts TEL AVIV, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the second quarter ended June 30, 2024. Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, stated, “We are pleased to report a number of recent milestones that have helped advance the clinical development of PRF-110, our lead drug candidate, targeting the post-operative extended...

Continue reading

CAPREIT Announces Increased August 2024 Distribution

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today its August 2024 monthly distribution in the amount of $0.125 per Unit (or $1.50 on an annualized basis). The August 2024 distribution will be payable on September 16, 2024 to Unitholders of record at the close of business on August 30, 2024. CAPREIT is Canada’s largest publicly traded provider of quality rental housing. As at June 30, 2024, CAPREIT owns approximately 64,200 residential apartment suites, townhomes and manufactured home community sites well-located across Canada and the Netherlands, with approximately $16.6 billion of investment properties in Canada and Europe. Since its Initial Public Offering in May 1997, CAPREIT has grown monthly cash distributions per Unit by 110%. For...

Continue reading

ERES REIT Declares August 2024 Monthly Distribution

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the August 2024 monthly cash distribution of €0.01 per Unit and Class B LP Unit (the “August Distribution”), being equivalent to €0.12 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on August 30, 2024, with payment on September 16, 2024. The Euro-denominated distribution will be paid in Canadian dollars based on the exchange rate on the date of payment (estimated C$0.01497 per Unit and Class B LP Unit). Registered Unitholders will be provided with an option to elect to receive such distribution in Euros rather than Canadian dollars. If no such election is made, registered Unitholders...

Continue reading

Flagship Communities Real Estate Investment Trust Announces August 2024 Cash Distribution

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (the “REIT”) (TSX:MHC.U; MHC.UN) announced today a cash distribution of US$0.0492 per REIT unit for the month of August 2024, representing US$0.59 per REIT unit on an annual basis. Payment will be made on or about September 16, 2024, to unitholders of record as of the close of business on August 30, 2024. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstances. About Flagship Communities Real Estate Investment Trust Flagship...

Continue reading

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyondLead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in the Phase 1 dose extension study in Australia COVID-19 program, ratutrelvir, completed the Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) study in Australia Oncology strategy includes investigator-sponsored trials (ISTs), planned to begin in H2 2024, adding a new dimension to the narazaciclib program, with continued investigator support for rigosertib Corporate update call planned for August 15, 2024 at 8:00...

Continue reading

Grab Reports Second Quarter 2024 Results

•   Revenue grew 17% year-over-year, or 23% on a constant currency basis to $664 million•   On-Demand GMV grew 13% year-over-year, or 18% on a constant currency basis to $4.4 billion•   Operating Loss improved by $121 million year-over-year to $(56) million•   Adjusted EBITDA improved by $81 million year-over-year to $64 million SINGAPORE, Aug. 15, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB) today announced unaudited financial results for the second quarter ended June 30, 2024. “We continued to harness the strength of the Grab ecosystem, and improved the usage frequency and reliability of our products and services. During the quarter, we achieved a new milestone, serving more users than ever at a record high of 41 million MTUs while delivering continued profitable growth at scale,” said Anthony Tan,...

Continue reading

Milestone Scientific Provides Business Update and Reports Financial Results for the Second Quarter of 2024

Secured Medicare price assignment for the CompuFlo® Epidural System in multiple U.S. states Gross margin for the second quarter of 2024 increased to 76.1% from 65.0% for the same period last year driven by an increase in U.S. e-commerce sales ROSELAND, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2024. Arjan Haverhals, CEO and President of Milestone Scientific, commented, “We are successfully advancing our reimbursement strategy for the CompuFlo® Epidural System, aimed at achieving nationwide coverage. Last month, we reached a significant milestone as we were granted a Medicare Part B Physician...

Continue reading

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate developments. “The first half of 2024 was marked by considerable corporate and clinical progress across the organization. We were encouraged by the bolus of data we presented at ASCO and EHA as they underscore the potential of a prexigebersen combination regimen as a safe and effective treatment for some of the most vulnerable cancer patients,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path...

Continue reading

Next Hydrogen Reports Q2 2024 Financial Results

MISSISSAUGA, Ontario, Aug. 15, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the second quarter ended June 30, 2024. “We are pleased to report that our second-generation system is in extended Factory Acceptance Testing which is the final stage prior to demonstration at an external customer site. Further, we are gaining traction with strategic partners and secured an order to deliver a green hydrogen production unit to demonstrate our unique capabilities for low-cost green ammonia production,” said Raveel Afzaal, President & CEO. “We remain grateful to our government for its support on our journey through $2M from Federal Economic Development Agency for Southern Ontario...

Continue reading

Bread Financial™ Provides Performance Update for July 2024

COLUMBUS, Ohio, Aug. 15, 2024 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated.  For themonth endedJuly 31, 2024   For themonth endedJuly 31, 2023  (dollars in millions)End-of-period credit card and other loans $ 17,659     $ 17,963  Average credit card and other loans (1) $ 17,588     $ 17,560  Year-over-year change in average credit card and other loans (1)   — %     1 %Net principal losses (2) $ 120     $ 108  Net loss rate (1)(2)   8.0 %     7.4 %  As ofJuly 31, 2024   As ofJuly 31, 2023  (dollars in millions)30 days + delinquencies...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.